L
Lu Sun
Researcher at University of California, Los Angeles
Publications - 20
Citations - 4496
Lu Sun is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Immunotherapy & Medicine. The author has an hindex of 7, co-authored 11 publications receiving 3069 citations.
Papers
More filters
Journal ArticleDOI
Genomic and transcriptomic features of response to anti-pd-1 therapy in metastatic melanoma
Willy Hugo,Jesse M. Zaretsky,Lu Sun,Chunying Song,Blanca Homet Moreno,Siwen Hu-Lieskovan,Beata Berent-Maoz,Jia Pang,Bartosz Chmielowski,Grace Cherry,Elizabeth Seja,Shirley H. Lomeli,Xiangju Kong,Mark C. Kelley,Jeffrey A. Sosman,Douglas B. Johnson,Antoni Ribas,Roger S. Lo +17 more
TL;DR: It is found that overall high mutational loads associate with improved survival, and tumors from responding patients are enriched for mutations in the DNA repair gene BRCA2, suggesting that attenuating the biological processes that underlie IPRES may improve anti-PD-1 response in melanoma and other cancer types.
Journal ArticleDOI
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.
Angel Garcia-Diaz,Daniel Sanghoon Shin,Blanca Homet Moreno,Justin Saco,Helena Escuin-Ordinas,Gabriel Abril Rodriguez,Jesse M. Zaretsky,Lu Sun,Willy Hugo,Xiaoyan Wang,Giulia Parisi,Cristina Puig Saus,Davis Y. Torrejon,Thomas G. Graeber,Begonya Comin-Anduix,Siwen Hu-Lieskovan,Robert Damoiseaux,Roger S. Lo,Antoni Ribas +18 more
TL;DR: Analysis of biopsy specimens from patients with melanoma confirmed interferon signature enrichment and upregulation of gene targets for STAT1/STAT2/STAT3 and IRF1 in anti-PD-1-responding tumors.
Journal ArticleDOI
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
Willy Hugo,Hubing Shi,Lu Sun,Marco Piva,Chunying Song,Xiangju Kong,Gatien Moriceau,Aayoung Hong,Kimberly B. Dahlman,Douglas B. Johnson,Jeffrey A. Sosman,Antoni Ribas,Roger S. Lo +12 more
TL;DR: High intra-tumoral cytolytic T cell inflammation prior to MAPKi therapy preceded CD8 T cell deficiency/exhaustion and loss of antigen presentation in half of disease-progressive melanomas, suggesting cross-resistance to salvage anti-PD-1/PD-L1 immunotherapy.
Journal ArticleDOI
Erratum: Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma (Cell (2016) 165(1) (35–44)(S009286741630215X)(10.1016/j.cell.2016.02.065))
Willy Hugo,Jesse M. Zaretsky,Lu Sun,Chunying Song,Blanca Homet Moreno,Siwen Hu-Lieskovan,Beata Berent-Maoz,Jia Pang,Bartosz Chmielowski,Grace Cherry,Elizabeth Seja,Shirley H. Lomeli,Xiangju Kong,Mark C. Kelley,Jeffrey A. Sosman,Douglas B. Johnson,Antoni Ribas,Roger S. Lo +17 more
Journal ArticleDOI
Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation
Chunying Song,Marco Piva,Lu Sun,Aayoung Hong,Gatien Moriceau,Xiangju Kong,Hong Zhang,Shirley H. Lomeli,Jin Qian,Clarissa C. Yu,Robert Damoiseaux,Mark C. Kelley,Kimberley B. Dahlman,Philip O. Scumpia,Jeffrey A. Sosman,Douglas B. Johnson,Antoni Ribas,Willy Hugo,Roger S. Lo +18 more
TL;DR: Comparing the transcriptomes of patient-derived tumors regressing on MAPK inhibitor (MAPKi) therapy against MAPKi-induced temporal transcriptomic states in human melanoma cell lines or murine melanoma in immune-competent mice helps identify adaptations such as PD-L2 operative tumor cell intrinsically and/or extrinsically early on therapy.